Clinical trial
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity
NCT07919405 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- November 11, 2026
- Completion date
- July 13, 2028
- Enrollment
- 1,408 (estimated)
- Sites
- 212
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 4 arms.
-
CagriSema
Participants will receive CagriSema subcutaneously once weekly.
-
Semaglutide
Participants will receive semaglutide subcutaneously once weekly.
-
Cagrilintide
Participants will receive cagrilintide subcutaneously once weekly.
-
Placebo
Participants will receive placebo subcutaneously once weekly.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP)
Measured in millimeters of mercury (mmHg).
Lead sponsor's other trials
Novo Nordisk A/S, most recent start first.
+1,402 more trials See the organization page
Similar trials
Same condition (Hypertension) and phase, most recent start first.
+584 more trials See the condition page